Pfizer Inc. (PFE.VI)
| Previous close | 23.97 |
| Open | 25.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.20 - 25.80 |
| 52-week range | 23.62 - 37.35 |
| Volume | |
| Avg. volume | 203 |
| Market cap | 154.498B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 73.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (6.55%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Business Wire
Pfizer Reports First-Quarter 2024 Results
NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).
- Business Wire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
- Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
